Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of pharmacological therapy of obesity in liver transplant candidates
2026-526044-12-00Phase 4Authorised
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of tirzepatide in obesity, sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: Change in body weight, BMI, and body fat composition. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on 2026-526044-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526044-12-00.